Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bremelanotide
- Development stage
- Approved
- Lead developer
- Palatin Technologies
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
Bremelanotide is a synthetic cyclic heptapeptide and melanocortin receptor agonist used for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts primarily by nonselectively activating several melanocortin receptors (MC1R, MC4R, MC3R, MC5R, and MC2R), with the highest potency at MC1R and MC4R. The precise mechanism by which it improves sexual desire is not fully understood but may involve stimulation of dopamine pathways in brain regions associated with sexual behavior. Bremelanotide is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. It was developed by Palatin Technologies and marketed under the brand name Vyleesi[1][2][3][4][8].
- Brand names
- Vyleesi
- Other names
- MCR Agonist
02
Targets
MC5R (Melanocortin 5 Receptor)MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)MC1R (Melanocortin Type 1 Receptor)
Beyond the preview
Go deeper on bremelanotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bremelanotide.